Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,431 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,448 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00492947 | Dendritic Cell Vaccine for Head and Neck Cancer(Dendritic) | withdrawn | Phase 1 | 0 | University of Maryland, BaltimoreOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT01707056 | The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma | withdrawn | N/A | 0 | Medstar Health Research InstituteOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT04041141 | Oral Stent Device for Radiation Treatments of Oral Cancers | withdrawn | — | 0 | Indiana UniversityOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | withdrawn | Phase 2 | 0 | Alain AlgaziOTHER | 0 | Oct 26, 2020 | clinicaltrials |
| NCT04058145 | AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT04093115 | Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | withdrawn | Phase 2 | 0 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2020 | clinicaltrials |
| NCT04276454 | Lymphedema Treatment in Head and Neck Cancer Patients | withdrawn | N/A | 0 | Endeavor HealthOTHER | 1 | Aug 13, 2020 | clinicaltrials |
| NCT03714867 | Pre-Operative Pregabalin for Post-Operative Pain in Head and Neck Cancer Surgery | withdrawn | Phase 4 | 0 | Augusta UniversityOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT00181220 | Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma | withdrawn | Phase 1 | 0 | Johns Hopkins UniversityOTHER | 1 | May 18, 2020 | clinicaltrials |
| NCT00367718 | Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma | withdrawn | Phase 2 | 0 | Johns Hopkins UniversityOTHER | 2 | May 18, 2020 | clinicaltrials |
| NCT03261180 | Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer | withdrawn | N/A | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT03323424 | Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers(IRAM) | withdrawn | Phase 2 | 0 | Institut de Cancérologie de la LoireOTHER | 1 | Jan 30, 2020 | clinicaltrials |
| NCT02686008 | Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC | withdrawn | Phase 1 | 0 | Yale UniversityOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT03342352 | Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Dec 20, 2019 | clinicaltrials |
| NCT02390739 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 16, 2019 | clinicaltrials |
| NCT03575234 | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03611205 | Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Aug 7, 2019 | clinicaltrials |
| NCT00387530 | Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Aug 2, 2019 | clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT03325465 | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)(PICH) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Antoine LacassagneOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02657850 | Head and Neck Cancer Treatment Related Dysphagia | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 4 | Mar 18, 2019 | clinicaltrials |
| NCT00899704 | Biomarkers in Tissue Samples From Patients Who Have Undergone Neck Dissection for Oral Cancer | withdrawn | — | 0 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02442739 | Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers | withdrawn | Early Phase 1 | 0 | Cedars-Sinai Medical CenterOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00894101 | Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation | withdrawn | Phase 2 / Phase 3 | 0 | University of California, IrvineOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01933269 | FACBC for Head and Neck Cancers | withdrawn | Early Phase 1 | 0 | Emory UniversityOTHER | 0 | Feb 5, 2018 | clinicaltrials |
| NCT01652456 | Alcohol and Tobacco Consumption in Patients With Head and Neck Cancer : Interest of an Addiction Support | withdrawn | N/A | 0 | Centre Oscar LambretOTHER | 1 | Jan 24, 2018 | clinicaltrials |
| NCT02628912 | Cardiopulmonary Fitness in Long-Term Survivors of HPV-related Oropharynx Cancers | withdrawn | — | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Jan 4, 2018 | clinicaltrials |
| NCT03238638 | A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Jan 4, 2018 | clinicaltrials |
| NCT02993991 | Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity(PRIMED-001) | withdrawn | Phase 1 | 0 | University Health Network, TorontoOTHER | 1 | Dec 29, 2017 | clinicaltrials |
| NCT02298595 | Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Julie E. Bauman, MD, MPHOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT02211027 | Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA | withdrawn | Phase 1 | 0 | Robert FerrisOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT01767961 | Modified Barium Swallow in Measuring Swallowing Function After Surgery in Patients With Oropharyngeal Cancer | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Aug 10, 2017 | clinicaltrials |
| NCT01545687 | CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy | withdrawn | Phase 3 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Aug 8, 2017 | clinicaltrials |
| NCT00257335 | Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer | withdrawn | Phase 2 | 0 | Nilam RamsinghaniOTHER | 0 | Jul 31, 2017 | clinicaltrials |
| NCT02726282 | Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences: a Cross Sectional Survey | withdrawn | — | 0 | Mayo ClinicOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT02593929 | Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer | withdrawn | Early Phase 1 | 0 | University of PittsburghOTHER | 0 | Jun 8, 2017 | clinicaltrials |
| NCT02251639 | Diagnostic Aids for Detection and Diagnosis of Oral Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 27, 2017 | clinicaltrials |
| NCT00937417 | S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Apr 24, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT02649530 | A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 30, 2016 | clinicaltrials |
| NCT01820312 | A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Aug 8, 2016 | clinicaltrials |
| NCT00627835 | Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) | withdrawn | Phase 1 | 0 | British Columbia Cancer AgencyOTHER | 1 | Jul 20, 2016 | clinicaltrials |
| NCT00041171 | Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery | withdrawn | Phase 3 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Jul 12, 2016 | clinicaltrials |
| NCT01184027 | Impact of Nutrition and Swallowing Function of Head and Neck Cancer Patients During the Course of Treatment | withdrawn | — | 0 | University of AlbertaOTHER | 1 | May 23, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Apr 30, 2021source: clinicaltrials